Copanlisib
| Clinical data | |
|---|---|
| Trade names | Aliqopa |
| Other names | BAY 80-6946 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617044 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | PI3-Kinase inhibitor |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 84.2% |
| Metabolism | CYP3A4/5 (≈90%), CYP1A1 (≈10%) |
| Elimination half-life | 39.1 hours (range: 14.6 to 82.4) |
| Excretion | Feces (64%), Urine (22%); 14% were not recovered |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H28N8O4 |
| Molar mass | 480.529 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
In November 2023, Bayer announced that it was withdrawing copanlisib from the US market.